Entrar/Registro  
INICIO ENGLISH
 
Medicina Cutánea Ibero-Latino-Americana
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio


ENVÍO DE ARTÍCULOS






>Revistas >Medicina Cutánea Ibero-Latino-Americana >Año 2010, No. 1


Iranzo FP
Dermatitis herpetiforme. Patogenia, diagnóstico y tratamiento
Med Cutan Iber Lat Am 2010; 38 (1)

Idioma: Español
Referencias bibliográficas: 53
Paginas: 5-15
Archivo PDF: 609.80 Kb.


Texto completo




RESUMEN

La dermatitis herpetiforme es una enfermedad ampollosa autoinmune poco frecuente. Las lesiones clínicas son polimorfos y el estudio de anatomía patológica es inespecífico en un porcentaje elevado de casos, por ello su diagnóstico puede pasar desapercibido si no se realiza estudio de inmunofluorescencia directa y las pruebas complementarias pertinentes. Se considera la manifestación cutánea de una enteropatía por sensibilidad al gluten, asintomática en un elevado numero de casos. Frecuentemente se asocia a otras enfermedades autoinmunes y existe un riesgo de desarrollo de linfoma no Hodgkin de células T. Su diagnóstico se basa en la clínica, pruebas tisulares (histopatología e inmunofluorescencia directa) y serológicas (anticuerpos anti-endomisio, anti-transglutaminasa tisular y anti-transglutaminasa epidérmica). La base del tratamiento es la dieta sin gluten estricta que debe instaurarse precozmente con la finalidad de evitar complicaciones posteriores y mantenerse de por vida. La sulfona y otros fármacos son útiles para inducir la remisión de los síntomas cutáneos hasta el inicio del efecto de la dieta.


Palabras clave: Dermatitis herpetiforme, enfermedad de Duhring, celiaquía, intolerancia al gluten.


REFERENCIAS

  1. Duhring LA. Dermatitis Herpetiformis. J Am Med Assoc 1884; 3: 225-9.

  2. Costello M. Dermatitis herpetiformis treated with sulphapyridine. Arch Dermatol Syph 1940; 41: 134.

  3. Cormane RH. Immunofluorescent studies of the skin in lupus erythematosus and other diseases. Pathol Eur 1967; 2: 170-80.

  4. Van der Meer JB. Granular deposits of immunoglobulin in the skin of patient with dermatitis herpetiformis: An immunofluorescent study. Br J Dermatol 1969; 81: 493-503.

  5. Marks J, Shuster S, Watson AJ. Small bowel changes in dermatitis herpetiformis. Lancet 1966; 2: 1280-2.

  6. Fry L, Keir P, McMinn RM, Cowan JD, Hoffbrand AV. Small-intestinal structure and function and hematological changes in dermatitis herpetiformis. Lancet 1967; 2: 729-33.

  7. Shuster S, Watson AJ, Marks J. Coeliac syndrome in dermatitis herpetiformis. Lancet 1968; 1: 1101-6.

  8. Fry L, Seah PP, Riches DJ, Hoffbrand AV:.Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. Lancet 1973; 1: 288-91.

  9. Dieterich W, Ehnis T, Bauer M,Donner P, Volta U, Riecken EO, Schuppan D. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797-801.

  10. Dieterich W, Laag E, Bruckner-Tuderman L, Reunala T, Kárpáti S, Zagoni T et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999; 113: 133-6.

  11. Sárdy M, Kárpáti S, Merkl B, Paulsson M and Smith N: Epidermal transglutaminase (Tgase3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747-57.

  12. Hull, CM, Liddle M, Hansen N, Meyer LJ, Schmidt L, Taylor T et al. Elevation of IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiformis. Br J Dermatol 2008; 159: 120-4.

  13. Jaskowski TD, Hamblin T, Wilson AR, Hill HR, Book LS, Meyer LJ et al. IgA anti-epidermal transglutaminase antibodies in dermatitis herpetiforrmis and celiac disease. J Inves Dermatol 2009; 129: 2728-30.

  14. Reunala T, Lokki J. Dermatitis herpetiformis in Finland. Acta Derm Venereol. 1978; 58: 505-10.

  15. Smith JB, Tulloch JE, Meyer LJ, Zone JJ, The incidence and prevalence of dermatitis herpetiformis in Utah. Arch Dermatol 1992; 128: 1608-10.

  16. Alonso-Llamazares J, Gibson LE,Rogers R. Clinical, pathological and immunopathological features of dermatitis herpetiformis: review of the Mayo Clinic experience. Int J Dermatol 2007; 46: 910-9.

  17. Meyer LJ, Zone JJ. Familial incidence of dermatitis herpetiformis. J Am Acad Dermatol 1987; 17: 643-7.

  18. Reunala T. Incidence of familial dermatitis herpetiformis. Br J Dermatol 1996; 134: 394-8.

  19. Hervonen K, Karell K, Holopainen P, Collin P, Partanen J, Reunala T. Concordance of dermatitis herpetiformis and celiac disease in monozygous twins. J Invest Dermatol 2000; 115: 990-3.

  20. Molberg O, Macdam SN, Korner R, Quarsten H Kristiansen C, Madsen L et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut- derived T cells in CD. Nat Med 1998; 4: 713-7.

  21. Korponay-Szabo IR, Vecsey Z, Kiralat R, Dalhbom I, Chirdo F, Nemes E et al. Deaminated gliadin peptides form epitopes that antitransglutaminase antibodies recognize. J Pediatr Gastroenterol Nutr 2008; 46: 253-61.

  22. Marietta EV, Rashtak S, Murray J A. Correlation analysis of celiac sprue tissue transglutaminase and deaminated gliadin IgG/IgA. World J Gastroenterol 2009; 15: 845-58.

  23. Meresse B, Chen Z, Ciszewski C, Tetiakova M, Bhagat G, Krausz TNet al. Coordinated induction by IL15 of a TCR-independent NKG2D signalling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 2004: 21: 357-66.

  24. Hall RP, Benbenisty KM, Mickle C, Takeuchi F, Streilein RD. Serum IL-8 in patients with dermatitis herpetiformis is produced in response to dietary gluten. J Invest Dermatol 2007; 127: 2158-65.

  25. Hall RP, Takeuchi F, Benbenisty KM, Streilein RD. Cutaneous endothelial cell activation in normal skin of patients with dermatitis herpetiformis associated with increased serum levels of IL-8, sE-Selectin, 7and TNF-α. J Invest Dermatol 2006; 126: 1331-7.

  26. Samolitis NJ, Hull CM,, Leiferman K M and Zone JJ. Dermatitis herpetiformis and partial IgA deficiency. J Am Acad Dermatol 2006; 54: S206-9.

  27. Donaldson M R, Zone J J, Schmidt L A, Taylor T B, Neuhausen S L, Hull C M, Meyer L J. Epidermal transglutaminase deposits in perilesional and uninvolved skin in patients with dermatitis herpetiformis. J Invest Dermatol 2007; 127: 1268-71.

  28. Caproni M, Antiga E, Melani L, Fabbri P. The Italian Group for Cutaneous Immunopathology. Guidelines for the diagnosis and treatment of dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2009; 23: 633-8.

  29. Piérard J. De l´aspect histologique des plaques erythémateuses de la dermatite herpetiforme de Duhring. Ann Dermatol syph 1963; 90: 121-33.

  30. Warren S J, Cockerell CJ. Characterization oh a subgroup of patients with dermatitis herpetifirmis with nonclassical histological features. Am J Dermatpoathol 2002; 24: 305-8.

  31. Zaenglein AL, Hafer L and Helm K F. Diagnosis of dermatitis ferpetiformis by an avidinbiotin-peroxidase metod. Arch Dermatol 1995; 131: 571-3.

  32. Marsh MN. Gluten, major histocompatibility complex and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity (“celiac sprue”). Gastroenterology 1992; 102: 330-54.

  33. Kárpáti S, Meurer M, Soltz W, Schrallhammer K, Krieg T, Braun-Falco O. Dermatitis herpetiformis bodies: ultraestructural study on the skin of patients using direct preembedding immunogold labelling. Arch Dermatol 1990; 126: 1469-74.

  34. Preisz K, Sárdy M, Horváth A, Kárpáti S. Immunoglobulin, complement and epidermal transglutaminase deposition in the cutaneous vessels in dermatitis herpetiformis. J Eur Acad Dermatol Venereol 2005; 19: 74-9.

  35. Clements SE, Stefanato CM, Bhogal B, Groves RW. Atypical dermatitis herpetiformis with fibrillar IgA deposition: CPC-8. Br J Dermatol 2007; 157: 17.

  36. Jones SAV, Bhogal BX, Black MM. Fibrillar IgA deposition may be associated with atypical dermatitis herpetiformia report of two cases. J Eur AcadDermatol Venereol 1996; 7: 270.

  37. Ko CJ, Colegio OR, Moss JE, McNiff JM. Fibrillar IgA deposition in dermatitis herpetiformisan underreported pattern with potential clinical significance. J Cutan Pathol 2009;(Epub ahead of print).

  38. BlaZone JJ, Meyer LJ, Petersen MJ. Deposition of Granular IgA Relative to Clinical Lesions in Dermatitis Herpetiformis. Arch Dermatol. 1996; 132: 912-8.

  39. Zone JJ. Skin manifestations of celiac disease. Gastroenterology 2005: 128; S87-S91.

  40. Rostom A, Murray J, Kagnoff M E. American Gastroenterological Association (AGA) institute technical review on the diagnosis and management of celiac disease. Gastroenterology 2006; 131: 1981-2002.

  41. Kumar V, Jarzabek-Chorzeska M, Sulej J, Karnewska K, Farrell T, Jablonska S. celiac disease and immunoglobulin A deficiency: how effective are the serological methods of diagnosis? Clin Diagn Lab Immunol 2002; 9: 1295-300.

  42. Korponay-Szabo IR, Dahlbom I, Laurila K, Koskinen S, Wolley N, Partanen J, Kovacs JB, Maki M, Hansson T. Elevation of IgG antibodies against tissue transglutaminase as a diagnostic tool for celiac disease in selective IgA deficiency. Gut 2003; 52: 1567-71.

  43. Chorzelski TP, Rosinska D, Beutner EH, Sulej J, Kumar V. Aggressive gluten challenge of dermatitis herpetiformis cases converts them from seronegative to seropositive for IgA-class endomysial antibodies. J Am Acad Dermatol 1988;18: 672-8.

  44. Rose C, Ambruster FP, Ruppert J, Igl B-W, Zillikens D and Shimanovich I. Autoantibodies against epidermal tranglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol 2009; 61: 39-43.

  45. Dahlbom I, Korponay-Szabó IR, Kovács JB, Szalai Z, Mäki M, Hansson T. Prediction of Clinical and Mucosal Severity of Coeliac Disease and Dermatitis Herpetiformis by Quantification of IgA/IgG Serum Antibodies to Tissue Transglutaminase. J Pediatr Gastroenterol Nutr 2009 Publish ahead of print.

  46. Sprukland A, Ingvarsson G, Falk ES, Knutsen I, Sollid LM, Thorsby E. Dermatitis herpetiformis and celiac disease are both associated with HLA-DQ (1*0501 1*02) or the HLA-DQ (1*03 1* 0302) heterodimers. Tissue Antigens 1997; 49: 29-34.

  47. Petaros P, Martelossi S, Tommasani A, Torre G, Caradonna M, ventura A. Prevalence of autoimmune disorders in relatives of patients with celiac disease. Dig Dis Sci 2002; 47: 1427-31.

  48. Cataldo F. Marino V. Increased Zone JJ. Increased prevalence of autoimmune diseases in first-degree relatives of patients with celiac disease. J Pediatr Gastroenterol Nutr 2003; 36: 470-3.

  49. Neuhausen SL, Steele L, Ryan S, Mousavi M, Pinto M, Osann E et al. Co-occurrence of celiac disease and other autoimmune diseases in celiacs and their first-degree relatives. J Autoimmun 2008; 31: 160-5.

  50. Viljamaa M, Kaukinen K, Pukkala E, Hervonen K, Reunala T, Collin P. Malignancies and mortality in patients with coeliac disease and dermatitis herpetiformis: 30-year population-based study. Dig Liver Dis 2006; 38: 374-80.

  51. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009; 373: 1480-93.

  52. Lewis NR, Logan RFA, Hubbard RB, West J. No increase in risk of fracture, malignancy or mortality in dermatitis herpetiformis: a cohort study. Aliment Pharmacol Ther 2008; 27: 1140-7.

  53. Bardella MT, Fredella C, Trovato C, Ermacora E, Cavalli R, Saladino V, Prampolini L. Longterm remission in patients with dermatitis herpetiformis on a normal diet. Br J Dermatol 2003; 149: 968-71.



>Revistas >Medicina Cutánea Ibero-Latino-Americana >Año2010, No. 1
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019